

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 1<sup>st</sup> January 2018

### ORDER

S. O. 02 In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S. O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

**Table**

| Sl. No. | Name of the Scheduled Formulation / Brand Name      | Strength   | Unit      | Manufacturer & Marketing Company  | Retail Price (Rs.) |
|---------|---|--|-----------|---|--------------------|
| 1.      | Cilnidipine + Metoprolol Tablet                     | Each film coated Bi- Layered tablet contains:<br>Cilnidipine 10mg,<br>Metoprolol Succinate IP 47.5mg eq. to Metoprolol Tartrate 50mg (ER)                              | 1 Tablet  | M/s Pure and Cure Healthcare Pvt Ltd. / M/s Intas Pharmaceuticals Pvt. Ltd. | 7.346              |
| 2.      | Metformin + Glimepiride + Voglibose Tablets         | Each tablet contains:<br>Metformin HCL 500mg (as sustained release form)<br>Glimepiride 1mg<br>Voglibose 0.3mg   | 1 Tablet  | M/s Sunglow Pharmaceuticals Pvt. Ltd. / M/s Intas Pharmaceuticals Ltd.      | 8.17               |
| 3.      | Rosuvastatin + Clopidogrel Capsule                  | Each Hard gelatin capsule contains:<br>Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg,<br>Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg                          | 1 Capsule | M/s Synokem Pharmaceuticals Ltd. / M/s Cadila Pharmaceuticals Ltd.          | 7.80               |
| 4.      | Telmisartan + Chlorthalidone Tablet (Tigatel CH 80) | Each film coated tablet contains:<br>Telmisartan IP 80mg,<br>Chlorthalidone IP 12.5mg  | 1 Tablet  | M/s Sun Pharma Laboratories Limited   | 6.713              |
| 5.      | Rosuvastatin + Clopidogrel Capsule                  | Each hard gelatin capsule contains:<br>Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As pellets)<br>Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd. / M/s Zydus Healthcare Ltd.                | 7.80               |
| 6.      | Paracetamol+Caff                                    | Each uncoated tablet contains:   | 1 Tablet  | M/s Dales   | 2.57               |

|     |  |  |              |   |        |
|-----|--|--|--------------|---|--------|
|     | eine+<br>Phenylephrine+<br>Diphenhydramine<br>Tablet (Sinus77) | Paracetamol-500mg<br>Caffeine (anhydrous)-30mg<br>Phenylephrine HCl-5mg<br>Diphenhydramine HCl-25mg  |              | Laboratories Pvt.<br>Ltd.   |        |
| 7.  | Atorvastatin +<br>Clopidogrel<br>Capsule                       | Each hard gelatin capsule<br>contains:<br>Atorvastatin Calcium IP eq. to<br>Atorvastatin 10mg,<br>Clopidogrel Bisulphate IP eq. to<br>Clopidogrel 75mg   | 1<br>Capsule | M/s Synokem<br>Pharmaceuticals<br>Ltd. / M/s Eris<br>Lifesciences Limited     | 8.394  |
| 8.  | Atorvastatin +<br>Clopidogrel<br>Capsule                       | Each hard gelatin capsule<br>contains:<br>Atorvastatin Calcium IP eq. to<br>Atorvastatin 20mg,<br>Clopidogrel Bisulphate IP eq. to<br>Clopidogrel 75mg   | 1<br>Capsule | M/s Synokem<br>Pharmaceuticals<br>Ltd. / M/s Eris<br>Lifesciences Limited     | 10.596 |
| 9.  | Gliclazide +<br>Metformin Tablet<br>(Glychek M +)              | Each uncoted tablet contains:<br>Gliclazide IP 40mg,<br>Metformin Hydrochloride IP<br>500mg  | 1 Tablet     | M/s Akums Drugs &<br>Pharmaceuticals<br>Ltd. / M/s Indoco<br>Remedies Limited | 4.354  |
| 10. | Atorvastatin +<br>Clopidogrel<br>Capsule (Atocor<br>CV 20mg)   | Each hard gelatin capsule<br>contains:<br>Atorvastatin Calcium IP eq. to<br>Atorvastatin 20mg (As two film<br>coated tablet Each containing<br>Atorvastatin 10mg)<br>Clopidogrel Bisulphate IP eq. to<br>Clopidogrel 75mg (As 2 film<br>coated 37.5mg each tablet) | 1<br>Capsule | M/s Windlas<br>Biotech Pvt. Ltd. /<br>M/s Dr. Reddy's<br>Laboratories Ltd.    | 10.596 |
| 11. | Atorvastatin +<br>Clopidogrel<br>Capsule (Avas 20<br>Gold)     | Each capsule contains:<br>Atorvastatin Calcium IP eq. to<br>Atorvastatin 20mg (As film<br>coated tablet)<br>Clopidogrel Bisulphate IP eq. to<br>Clopidogrel 75mg (As 2 film<br>coated 37.5mg each tablet)  | 1<br>Capsule | M/s Micro Lab. Ltd.   | 10.596 |
| 12. | Atorvastatin +<br>Clopidogrel<br>Capsule (Astin 20<br>Gold)    | Each capsule contains:<br>Atorvastatin Calcium IP eq. to<br>Atorvastatin 20mg (As film<br>coated tablet)<br>Clopidogrel Bisulphate IP eq. to<br>Clopidogrel 75mg (As 2 film<br>coated 37.5mg each tablet)  | 1<br>Capsule | M/s Micro Lab. Ltd.   | 10.596 |
| 13. | Rosuvastatin +<br>Clopidogrel<br>Capsule                       | Each hard gelatin capsule<br>contains:<br>Rosuvastatin Calcium IP eq. to<br>Rosuvastatin 10mg,<br>Clopidogrel Bisulphate IP eq. to<br>Clopidogrel 75mg   | 1<br>Capsule | M/s Synokem<br>Pharmaceuticals<br>Ltd. / M/s Eris<br>Lifesciences Limited     | 13.37  |
| 14. | Rosuvastatin +<br>Clopidogrel<br>Capsule                       | Each hard gelatin capsule<br>contains:<br>Rosuvastatin Calcium IP eq. to<br>Rosuvastatin 20mg,   | 1<br>Capsule | M/s Synokem<br>Pharmaceuticals<br>Ltd. / M/s Eris<br>Lifesciences Limited     | 7.80   |

|  |  |  |  |  |  |
|--|--|--|--|--|--|
|  |  | Clopidogrel Bisulphate IP eq. to<br>Clopidogrel 75mg |  |  |  |
|--|--|--|--|--|--|

Note:

- (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- (f) The concerned manufacturer of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturer, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (h) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/184/52/2017/F

F. No. 8(52)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)  
Assistant Director